linjc16/ctgov huggingface dataset:
Comparison of Aneuploidy Risk Evaluations

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multi-center observational study designed to compare the test results of the Verinata Health Prenatal Aneuploidy Test to results of conventional prenatal screening for fetal chromosome abnormalities in 'all-risk' pregnancies.

Official Title
-----------------
Performance of the Verinata Health Prenatal Aneuploidy Test Compared to Current Fetal Aneuploidy Screening Results and Pregnancy Outcomes in an 'All-Risk' Population

Conditions
-----------------
Pregnancy, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turners Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older at enrollment Clinically confirmed pregnancy Gestational age ≥8 weeks, 0 days Planned or completed prenatal serum screening* (drawn during 1st and/or 2nd trimester) Pregnancy records accessible and available for data collection (e.g., results from screening, ultrasound examinations, invasive prenatal procedures if performed, and newborn hospital discharge exam) Able to provide consent for participation using language appropriate forms Exclusion Criteria: Invasive prenatal procedure (amniocentesis or CVS) performed within 2 weeks prior to enrollment Prenatal screening determination by Nuchal Translucency (NT) measurement only

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All-risk pregnant women<br>All-risk pregnancies undergoing conventional forms of prenatal screening | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of screen positive rates between investigational testing results and conventional screening results (standard of care). | The primary outcome of this study is the false positive rate of fetal aneuploidy detection for chromosome 21, 18, and 13 by the Verinata Health Prenatal Aneuploidy Test and screen positive rate for fetal trisomy (T21) and trisomy (T18) by conventional prenatal screening methods. Birth outcomes, or karyotype if available, will be used as the reference standard. | 12 months |
Ventilator-associated Pneumonia (VAP) and Humidification System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which humidification system is more effective in preventing pneumonia in mechanically ventilated patients. The study will compare a heat and moisture exchanger versus heated humidification.

Official Title
-----------------
Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification

Conditions
-----------------
Ventilator-associated Pneumonia

Intervention / Treatment
-----------------
* Device: HME filter Twin Star 55, Drager Medical, Germany
* Device: Heated humidification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients expected to require mechanical ventilation for at least 48 hours Exclusion Criteria: Patients < 18 yo and pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HME filter<br> | Device: HME filter Twin Star 55, Drager Medical, Germany<br> <br> |
| Experimental: Heated humidificator MR 730 Fisher & Paykel<br> | Device: Heated humidification<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAP incidence |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of mechanical ventilation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mechanical Ventilation, Humidification system, Patients submitted to mechanical ventilation for at least 48 hours
Effects of Curcumin on Inflammation and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Study Overview
=================
Brief Summary
-----------------
The study will be a randomised, double blinded, placebo controlled design. It will include 2 groups : trial group and placebo group Patients in both groups are children on regular hemodialysis The patients in the trial group will receive Curcumin capsule 1 gm for 3 months , and the placebo group will receive a placebo capsule for 3 months All patients will be evaluated clinically, and laboratory at baseline, at 3 months after end of supplementation.

Official Title
-----------------
Effects of Curcumin on Inflammation and Oxidative Stress in Paediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Conditions
-----------------
Pediatric Patients Having Renal Failure and on Regular Hemodialysis

Intervention / Treatment
-----------------
* Dietary Supplement: Curcumin capsules 1 gm
* Dietary Supplement: Placebo capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female pediatric patients with weight of at least 30 kilograms. Undergoing regular hemodialysis for at least 6 months. Exclusion Criteria: Bleeding disorders. Chronic liver disease. Diabetes mellitus. Autoimmune diseases. Receiving drugs that are contraindicated, or have major interactions with curcumin, and can't be discontinued or replaced. Receiving corticosteroids, or immune-suppressants. Patients taking any antioxidant supplements including vitamin E, ascorbic acid, omega -3 fatty acid, or L-carnitine within 3 months prior to enrollment in our study.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Trial group<br>Children on regular hemodialysis whose weight 30 kg or above | Dietary Supplement: Curcumin capsules 1 gm<br>* Dietary supplement<br>|
| Placebo Comparator: Placebo group<br>Children on regular hemodialysis whose weight 30 kg or above | Dietary Supplement: Placebo capsule<br>* placebo corn starch<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammatory marker | high sensitivity C reactive protein (CRP) at baseline before supplementation and after 3 months of supplementation | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxidative stress markers | Serum tumor necrotizing factor alpha (TNF alpha)and malondialdehyde (MDA)at baseline and after 3 months of supplementation | 3 months |
Surgical Treatment for ODS With Rectal Prolapse Surgical Treatment for Rectal Prolapse

Study Overview
=================
Brief Summary
-----------------
Chronic obstinate constipation is hard to deal with in clinic. Especially for obstructed defecation syndrome(ODS). Rectal prolapse is the most common type of ODS. Lots of surgical procedures have been suggested for it but with unsatisfactory results.To develop new surgical treatment and to provide higher quality proof for this intractable condition is of significance.

Official Title
-----------------
Laparoscopica Hindgut Resection Plus Rectum Suspention Compare With Transanal Rectal Mucosa Resection for ODS With Rectal Prolapse

Conditions
-----------------
Constipation by Outlet Obstruction

Intervention / Treatment
-----------------
* Procedure: TARMR
* Procedure: LARSC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with ODS by defecography, coloscopy, barium enema and dynamic MRI. Patients should accord with Rome IV criteria. Exclusion Criteria: Severe heart or other organ disease. test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transanal rectal mucosa resection<br>TARMR: Transanal resection of rectal mucosa for at least 5cm in length. | Procedure: TARMR<br>* Transanal resection of rectal mucosa for at least 5cm in length.<br>|
| Laparoscopic rectal suspension and colectomy<br>LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically | Procedure: LARSC<br>* We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wexner constipation score | The Wexner constipation score should be filled out | 2019.1-2019.12 | 
| patients' satisfaction rate | The researcher will statistic the satisfaction rate of the patients | 2019.1-2019.12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| short period complications | postoperative 30-day complications | 2018.1-2019.12 | 
| operative time | the total operative time | 2018.1-2019.12 | 
| quality of life | SF-36 form | 2019.1-2019.12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
constipation, surgery
Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.

Official Title
-----------------
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: PBT2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of probable early Alzheimer's disease stable dose of acetylcholinesterase inhibitor community dwelling stable medical condition Exclusion Criteria: unstable and significant medical conditions recurrent major psychiatric disorder treatment with memantine

Ages Eligible for Study
-----------------
Minimum Age: 56 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: PBT2|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  | Study duration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in biomarkers; Change from baseline in cognitive and global function scales |  | Study duration |
Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.

Official Title
-----------------
Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine/naloxone


Participation Criteria
=================
Eligibility Criteria
-----------------
Male and non-pregnant female subjects seeking outpatient treatment for opioid dependence with physiological features without serious medical or psychiatric disorders.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine/naloxone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Opiate abstinence |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
opioid dependence, behavioral intervention
Medical Imaging Characteristics of Patient With Unclassified Acute Cervical Pain

Study Overview
=================
Brief Summary
-----------------
Some cases of acute antero-lateral cervical pain cannot be accurately classified by medical imaging (ultrasound and/or magnetic resonance imaging and/or CT-scan) : imaging rules out carotid dissection, carotid occlusion or vasculitis as well as musculoskeletal causes and thus the pain is considered of unknown origin. The investigators hypothesize that in such cases perivascular inflammation of the carotid may be involved. This study aims at systematically reviewing medical files (including imaging) of patients suffering from acute cervical pain in which carotid dissection, carotid occlusion or vasculitis as well as musculoskeletal causes have been ruled out by ultrasound and/or magnetic resonance imaging and/or CT-scan

Official Title
-----------------
Medical Imaging Characteristics of Patient With Unclassified Acute Cervical Pain

Conditions
-----------------
Carotidynia

Intervention / Treatment
-----------------
* Other: systematic review of medical imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient with acute cervical pain Presence of at least one medical imaging modality of the neck : ultrasound with doppler imaging, magnetic resonance imaging, CT-scan Medical imaging of the neck includes dedicated vessel analysis Absence of definite diagnosis for the cause of the pain after imaging Exclusion Criteria: Musculoskeletal cause of the pain Carotid dissection Carotid occlusion Carotid vasculitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cases of unclassified acute cervical pain<br> | Other: systematic review of medical imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of cases with perivascular inflammation of the carotid on medical imaging |  | Within 2 weeks after the first consultation for acute cervical pain |
GWAS Research of Lung Cancer in Tianjin

Study Overview
=================
Brief Summary
-----------------
To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

Detailed Description
-----------------
Eligibility criteria: nonsmoker female age between 35 and 80 no other types of tumors history frequency-matched cases and controls on gender and age Outcome measures: OR(odds ratio) RR(risk ratio) CI(confidence interval) SAS software

Official Title
-----------------
GWAS Research of Lung Cancer by Department of Epidemiology and Biostatistics in Tianjin Medical University Cancer Institute and Hospital

Conditions
-----------------
Non-small Cell Lung Cancer, Primary Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-small cell lung cancer Age from 35 to 80 years old Female Non-smokers Frequency-matched on age and gender Exclusion Criteria: Previous medical history of cancer Previous radiotherapy Previous chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Female lung cancer group<br>Female, non-smoker, non-small cell lung cancer | |
| Health control<br>Female, non-smokers, no lung cancer or other types of cancers' healthy population | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia | A GWAS reported a novel association between the TP63 locus and risk of lung adenocarcinoma; however, this association did not achieve genome-wide significance among never-smoking males or females. We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China. Genetic variation in rs10937405 was associated with lung adenocarcinoma. Our findings provide strong evidence that genetic variation in TP63 is associated with risk of lung adenocarcinoma among non-smoking females. | 2011-12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genome-wide association studies(GWAS), Single nucleotide polymorphism(SNP), Lung cancer
Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.

Official Title
-----------------
Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model

Conditions
-----------------
Epithelial Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking surgery Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin Patients who have signed approved informed consent Exclusion Criteria: Uncontrolled medical disease Active infectious disease Previous pelvic radiation therapy Previous chemotherapy (prospective cohort) Patients with disease which can cause neutropenia Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort). Pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Training cohort<br>This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles. | |
| Validation cohort<br>This is a retrospective cohort for validation of a risk prediction model developed using training cohort. This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk prediction model for grade 3-4 chemotherapy induced neutropenia |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between mannose-binding lectin 2 gene SNP and neutropenia |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neutropenia, Paclitaxel, Carboplatin, Epithelial ovarian cancer